Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software | News
Search Refinements

IT & Software News

View news from other Pharmaceutical sectors:
76-90 of 1569 results
Syncona, UCLB form cancer immunotherapy firm Autolus
Syncona and UCL Business, the wholly-owned technology transfer company of University College London, announce the creation of Autolus Limited, a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours.
Automation > IT & Software > News
Trovagene expands clinical collaboration with Genomac
Trovagene, announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic.
Automation > IT & Software > News
Critical Outcome Technologies planning phase I trial of COTI-2 in recurrent head and neck cancers
Critical Outcome Technologies, the biopharmaceutical company that uses machine learning to rapidly develop targeted therapies, announced today that it has executed a material transfer agreement ("MTA") with Dr. John Yoo, MD, FRCSC, FACS, and his team at the London Health Sciences Centre's London Regional Cancer Program and Western University, for the continued evaluation of COTI-2 for the treatment of patients with recurrent head and neck squamous cell cancer ("HNSCC").
Automation > IT & Software > News
Spark begins Phase I/II trial of SPK-CHM to treat Choroideremia
By PBR Staff Writer
US-based gene therapy company Spark Therapeutics has started enrollment in a Phase I/II clinical trial of its product candidate, SPK-CHM, to treat patients with choroideremia (CHM), an X-linked inherited retinal dystrophy.
Automation > IT & Software > News
Oncore agrees to merge with Tekmira to develop NVP018 for hepatitis B treatment
US biotechnology company OnCore Biopharma (OnCore), which has licensed NeuroVive’s drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with Canadian listed RNAi therapeutics company Tekmira Pharmaceuticals (Tekmira).
Automation > IT & Software > News
Evotec enters into research collaboration with C4X Discovery
By PBR Staff Writer
German drug discovery firm Evotec and UK-based C4X Discovery Holdings (C4XD) have entered into a research collaboration to optimize Orexin-1 selective inhibitors discovered through C4XD's NMR technology.
Automation > IT & Software > News
Oramed granted patent in Israel for Oral Administration of GLP-1
Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the Israel Patent Office has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Exenatide."
Automation > IT & Software > News
Dose of Nature launches new CBD product line
Utah-based Dose of Nature launched a state-of-the-art CBD (Cannabidiol) product line, applying proprietary technologies to create the first nano CBD and water-soluble CBD products in the market.
Automation > IT & Software > News
Janssen, Vedanta enter license deal for lead microbiome pharmaceutical candidate
By PBR Staff Writer
Janssen Biotech has entered into a license agreement with Vedanta Biosciences for its lead microbiome pharmaceutical candidate (VE202), which showed efficacy in published preclinical studies using models of autoimmune disease.
Automation > IT & Software > News
Alnylam, Isis form new agreement in RNA Therapeutics
Isis Pharmaceuticals, and Alnylam Pharmaceuticals, leaders in RNA-targeted therapeutics, announced today they have formed a new agreement, extending their existing strategic partnership – formed originally in 2004 – to lead the development and commercialization of RNA therapeutics.
Automation > IT & Software > News
X-Chem, Janssen to advance new candidates to treat inflammatory diseases
X-Chem, a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Automation > IT & Software > News
Novartis to use CRISPR technology platforms for new medicines
By PBR Staff Writer
Swiss pharmaceutical firm Novartis has signed collaboration and licensing agreements with Intellia Therapeutics and Caribou Biosciences to develop new medicines and drug discovery tools with CRISPR genome editing technology.
Automation > IT & Software > News
Gamida Cell's NiCord gets FDA and EMA orphan drug status
Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS).
Automation > IT & Software > News
Amgen, Kite Pharma enter into cancer immunotherapy collaboration
Amgen and Kite Pharma announced that the two companies have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy (eACT) platform and Amgen's extensive array of cancer targets.
Automation > IT & Software > News
EpiVax enters license deal with Novozymes to advance pioneering treatment of autoimmune diseases
Novozymes' Veltis albumin-based half-life extension platform will help move Tregitope treatment for autoimmune diseases closer to clinical development.
Automation > IT & Software > News
76-90 of 1569 results